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Abstract  
Background 
Kawasaki disease (KD) is an acute pediatric vasculitis in which host genetics 
influence both susceptibility to KD and the formation of coronary artery aneurysms. 
Variants discovered by genome-wide association studies (GWAS) and linkage studies 
only partially explain the influence of genetics on KD susceptibility.  
Methods and Results 
To search for additional functional genetic variation, we performed pathway and 
gene stability analysis on a GWAS dataset. Pathway analysis using European GWAS 
data identified 100 significantly associated pathways (p< 5 x10-4). Gene stability 
selection identified 116 single nucleotide polymorphisms (SNPs) in 26 genes that were 
responsible for driving the pathway associations and gene ontology analysis 
demonstrated enrichment for calcium transport (p=1.05 x10-4). Three SNPs in solute 
carrier family 8 member 1 (SLC8A1), a sodium/calcium exchanger encoding NCX1, 
were validated in an independent Japanese GWAS dataset (metaanalysis p=0.0001). 
Patients homozygous for the A (risk) allele of rs13017968 had higher rates of coronary 
artery abnormalities (p=0.029). NCX1, the protein encoded by SLC8A1, was expressed 
in spindle-shaped and inflammatory cells in the aneurysm wall. Increased intracellular 
calcium mobilization was observed in B cell lines from healthy controls carrying the risk 
allele.  
Conclusion 
 Pathway-based association analysis followed by gene stability selection proved 
to be a valuable tool for identifying risk alleles in a rare disease with complex genetics. 
The role of SLC8A1 polymorphisms in altering calcium flux in cells that mediate 
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coronary artery damage in KD suggests that this pathway may be a therapeutic target 
and supports the study of calcineurin inhibitors in acute KD.  
 
Keywords:  
Kawasaki disease, aneurysm, pathway analysis, calcium signaling pathway, sodium 
calcium exchanger  
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Introduction 
Kawasaki disease (KD) is an acute, self-limited vasculitis of young children that 
results in coronary artery aneurysms (CAA) in 20% of untreated patients and ~5% of 
patients treated with intravenous immunoglobulin (IVIG)1. Although the etiology of KD 
remains unknown, the current paradigm is that host genetics play an important role in 
susceptibility and disease outcome with  a 10-50-fold higher incidence in children of 
Asian descent compared to those of European descent2. Although the association of six 
single nucleotide polymorphisms (SNPs) with KD susceptibility has been discovered by 
genome-wide association studies (GWAS) and linkage studies and validated in different 
ethnic groups, these variants explain only a fraction of disease risk3. GWAS is best 
suited to the discovery of strongly associated SNPs. However, in a complex genetic 
disease such as KD, susceptibility may be influenced by variation in several weakly 
associated genes in the same biological pathway. To discover additional variants 
implicated in disease susceptibility and aneurysm formation, we performed a pathway-
based analysis followed by gene stability selection to find the genes responsible for 
driving the pathway association (Figure 1). This approach had previously been used to 
identify novel susceptibility genes in rheumatoid arthritis, another inflammatory disorder 
with complex genetics4. The top variants were further tested for association in a 
Japanese KD GWAS dataset. Three SNPs in Solute Carrier Family 8, Member 1 
(SLC8A1) were validated and their protein product, NCX1, studied for genotype-
phenotype associations, expression in KD autopsy tissues, and patterns of gene 
expression in whole blood.   
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Materials and Methods 
Subjects  
The recruitment of KD patients and the details of their clinical presentation and 
diagnosis have been previously described5, 6. The classifications of CA status are 
described in the Supplemental methods. The Institutional Review Boards of the 
participating centers reviewed and approved this study and parental consent and assent 
as appropriate were obtained from parents and participants. 
Control DNA and EBV transformed B-cell lines were obtained from a healthy 
adult population-based cohort from The Centre for Applied Genomics (TCAG) at The 
Hospital For Sick Children, Toronto, Canada.  
ECG analysis  
 Fifty eight ECGs were available during acute phase (illness day ≤16) (AA n=16 
and CC n=42). Fifteen lead ECGs were interpreted by one investigator (JCP, an 
experienced pediatric electrophysiologist), blinded to allele status of the subject. Details 
are described in supplemental methods.. 
Imputation and meta-analysis using imputed GWAS data 
GWAS data imputation was performed in three steps: quality control (QC), pre-
phasing, and imputation7. Details are described in supplemental methods.  
Pathway and gene stability analysis 
Details of the analytic strategy have been previously published4. In brief, using 
genotype data from a GWAS comprising 405 KD patients and 6,252 controls of 
European ancestry5, we employed a pathway-based analysis using our previously 
reported cumulative trend test statistic8 to assess the association between KD and the 
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cumulative genetic variation in biological pathways, before taking the genes in the top-
100 significantly associated pathways forward to a gene-based stability selection4, to 
identify the genes driving the pathway association. We included only SNPs with a p 
value between 10-2 and 10-6 as previous experience has demonstrated that including 
more significant pathways leads to a greater false discovery rate. Pathways (n=2341 
containing ~9000 genes) were assembled using the Molecular Signatures Database 
(MSigDB) Pathway Commons database (University of Toronto, MSKCC - 
Computational Biology Center) as well as custom pathways based on literature 
searches and Ingenuity Pathways Analysis (http://www. ingenuity.com/). Association 
between KD susceptibility and variants found by this approach were validated in a 
Japanese GWAS dataset with 428 cases and 3379 controls9.  
Immunohistochemical (IHC) staining of tissue 
IHC was performed as previously described10. Anti-human NCX1 mouse-
monoclonal antibody (1:100 dilution, ab2869, Abcam) or rabbit IgG (negative control) was 
used to stain the tissues10.  
Calcium flux analysis by Fluorescence Activated Cell Sorting (FACS)  
 Intracellular calcium [Ca2+]i mobilization in EBV infected B-cells was acquired 
using Fluo-4/AM and Fura Red (Life Technologies) after Ionomycin (1M) addition. 
Details are described in supplemental methods. 
Expression quantitative trait loci (eQTL) analysis 
Systematic eQTL analyses using previously published transcriptome data11 was 
assessed on the discovered SNPs by grouping subjects into three groups (x-axis) using 
their genotypes followed by plotting the corresponding gene expression levels (y-axis). 
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One-way ANOVA and t-test were performed to test for differential expression 
among/between genotype groups. 
Statistical analysis 
Associations between genetic variants and the Z-worst for the coronary arteries 
were performed using non-parametric tests due to the non-normality of the Z-score. P-
values were calculated by Mann–Whitney U test for continuous variables and chi test or 
Fisher’s exact T-test for categorical variables. For the comparison of more than three 
variants, the Kruskal-Wallis test was used. 
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Results  
Pathway analysis and gene stability selection 
Association of the pathways with KD susceptibility was calculated using our 
European descent GWAS dataset (405 KD subjects, 6252 Controls) (Figure 1)5. The 
SNPs with p-values <0.01 and >10-6 were included in the pathway analysis4, which 
identified 100 pathways significantly associated with KD susceptibility with p < 5x10-4 
(Figure 1, Supplemental Table S1). This p-value was chosen to give a good balance 
between truly associated pathways and false positives4. Gene stability selection that 
was applied in an analysis of rheumatoid arthritis4 identified 26 genes with 116 SNPs 
responsible for driving the pathway association (Supplemental Table S2). In order to 
characterize the function of these 26 genes, we performed a gene ontology (GO) 
functional enrichment analysis (https://david.ncifcrf.gov/home.jsp). This analysis 
revealed significant enrichment in six functional GO terms with p<5x10-4  with calcium 
ion transport (GO:0006816, p=1.05x10-4) at the top (Supplemental Table S3). Six GO 
terms included five calcium channel genes: calcium channel, voltage-dependent, L type, 
alpha 1C subunit (CACNA1C), calcium channel, voltage-dependent, alpha 2/delta 
subunit 3 (CACNA2D3), calcium channel, voltage-dependent, beta 2 subunit 
(CACNB2), Solute Carrier Family 8, Member 1 (SLC8A1), and ryanodine receptor 2 
(RYR2) (Supplemental Table S3 and Supplemental Figure S1 and Figure 2). The top 
three pathways (acetylcholine pathway, endothelial release factors, and nitric oxide 
(NO) pathways) included 218, 301, and 78 genes, respectively. The genes responsible 
for driving the association of the pathways with KD susceptibility comprised seven of the 
26 genes that passed gene stability selection. Of these seven genes,  four were calcium 
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channel genes: CACNA1C, CACNB2, SLC8A1 and RYR2 (Table 1). Four of these 
calcium channel genes were in the top three pathways compared to only three of 18 
non-calcium channel genes (p=0.01). Therefore, the top ranked three pathways were 
enriched for calcium channel genes and this pointed to genetic variants in calcium 
channel genes as important in KD susceptibility.   
Since there was no independent European descent cohort with which to validate 
the SNPs discovered by the gene stability analysis, the association of the 40 SNPs in 
seven genes in the top three pathways was tested in an imputed Japanese GWAS 
dataset9. Three SNPs from SLC8A1 were associated with KD susceptibility in the 
Japanese dataset (nominal p: 0.005-0.0006 in European and 0.048-0.006 in Japanese) 
(Table 2). SLC8A1 was a member of 18 different pathways (Supplemental Table S1) 
including the top three pathways. The three validated SLC8A1 SNPs (rs10490051, 
rs13017968 and rs12989852) were in the same LD block with the cluster of associated 
SNPs identified by the European descent GWAS (Figure 2). The validated SNPs were 
located 80kb downstream from the splice donor site of the first exon that was shared by 
all of the15 transcript variants of SLC8A1 (Supplemental Figure S2).  
Characteristics of KD patients by genotype 
To determine if risk alleles in SLC8A1 influenced clinical parameters and disease 
outcome in KD patients, as a function of genotype, we compared demographic, clinical, 
and laboratory data from an independent cohort of 161 well-phenotyped KD patients 
who were also genotyped using the Illumina 1 million SNP chip (Figure 1B). The 
characteristics of 161 patients grouped by SLC8A1 rs13017968 genotype are 
summarized in Table 3. Subjects who were homozygous for the risk allele were also 
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more likely to develop aneurysms/dilation (14 of 25 (56%) homozygotes for the risk 
allele (A) vs. 40 of 136 (29%) with the AC+CC genotype) (p=0.018) and have a higher 
maximum Z score (median 2.8 (inter-quantile range (IQR) 1.3-3.5) for AA genotype vs. 1.7 
(1.1-2.6) AC+CC, p=0.049) for the internal diameter of the right (RCA) and left anterior 
descending (LAD) coronary arteries despite having a similar age distribution and 
median illness day at diagnosis compared to subjects without CAA. For a more robust 
analysis, we added additional patients with aneurysms (n=91) and normal coronary 
arteries (n=92) who were genotyped only for SLC8A1 rs13017968 (Supplemental 
TableS4). Homozygotes for the risk allele (n=55) in this expanded cohort were more 
likely to develop coronary artery aneurysms/dilation (31/55 (56%) vs. 24/55 (44%) 
p=0.029) (Supplemental TableS5). This suggests that SLC8A1 rs13017968 may 
influence both KD susceptibility as well as the risk of aneurysm formation and dilatation. 
Although SLC8A1 rs10490051 and rs12989852 showed a similar trend, homozygosity 
for these alleles was not significantly associated with aneurysm development (p=0.08 
for rs10490051 and p=0.2 for rs12989852). Therefore, we focused on rs13017968 for 
the following genotype-phenotype analyses. A higher percentage of Asian subjects was 
homozygous for the risk allele compared to the other ethnic groups, which was 
consistent with the percentages in the 1,000 Genomes database  (Supplemental Table 
S6), but no other unique characteristics were noted in subjects homozygous for the risk 
allele.   
SLC8A1 SNPs and ECG 
The association of genetic variants of SLC8A1 with QT interval has been 
reported12 . Therefore, we tested the potential association of SLC8A1 genetic variants 
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with electrocardiogram (ECG) abnormalities in KD patients. There were no significant 
differences in PR, QRSd, QTc, QT dispersion and Tp-e on the acute (pre-treatment) 
ECG by genotype (data not shown).  
NCX1 in coronary artery aneurysms  
Since patients homozygous for the SLC8A1 risk allele had a higher rate of 
coronary artery aneurysm formation, we explored the local expression of SLC8A1 in KD 
autopsy tissues. SLC8A1 encodes sodium calcium exchanger 1, NCX1, that is 
expressed on the cell membrane and functions as a bi-directional sodium/calcium 
channel. NCX1 is required to create a myofibroblast phenotype13. We performed 
immunohistochemical staining on the coronary artery from a 3 month old Caucasian 
male (CC wild type homozygous at rs1313017968) who died on illness day 12 with 
CAA. In these tissues, we previously demonstrated myofibroblast-like spindle-shaped10. 
We also stained coronary artery tissue from a 3y 7m-old Caucasian male (genotype 
unavailable due to unamplifiable DNA in formalin-fixed tissue) who died on illness day 7. 
NCX1 was expressed on spindle-shaped cells with a myofibroblast phenotype in the 
thickened intima (Figure 3 A1, C1), smooth muscle cells (Figure 3 A2, C2) and 
fibroblast-like, spindle-shaped cells in the adventitia (Figure 3 A3, C3). NCX1 
expression was also detected in round, inflammatory cells infiltrating the arterial wall 
(Figure 3 A4, C4). The coronary arterial wall from a 9 month-old infant who died of acute 
pneumonia and thus served as a control showed no NCX1 staining in the intima, media, 
or adventitia (Figure 3 E1-3) and no infiltration of inflammatory cells. Cardiomyocytes 
from KD autopsies, but not the control patient, also showed positive staining for NCX1 
(Figure 3 G-L).  
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Intracellular calcium mobilization as a function of genotype 
To determine the role of NCX1 on intracellular calcium [Ca2+]i levels and its 
mobilization, healthy adult controls from a population-based biorepository were 
genotyped at rs13017968 and EBV-transformed B cells from individuals with the AA 
(n=3), AC (n=2) and CC (n=3) genotypes were selected for functional assays. Cells 
were loaded with the ratiometrically opposite Ca2+ indicator dyes Fluo4AM and 
Fura3AM and [Ca2+]i levels were measured using flow cytometry. At the basal level, 
cells with the AA genotype showed increased [Ca2+]i when compared with AC and CC 
genotypes (Figure 4), suggesting that the NCX1 AA genotype has a decreased ability to 
exclude Ca2+ from the intracellular compartment in the resting state in transformed B 
cell lines. Furthermore, when stimulated with ionomycin, the B cells with the AA 
genotype showed increased [Ca2+]i flux when compared to cells with the AC and CC 
genotypes (Figure 4), suggesting an exaggerated response to stimuli in the AA 
genotype resulting in a marked increase in [Ca2+]i with stimulation. Thus the 
polymorphism at rs1313017968 is associated with a functional difference in regulation 
of [Ca2+]i at rest and following stimulation.  
Whole blood transcriptome analysis in KD patients 
A subset of the 161 genotyped KD subjects (n=146) were also analysed by 
microarray, which allowed eQTL analysis for the risk alleles in SLC8A1 (Figure 1B). 
Patients homozygous for the risk allele had increased expression of solute carrier family 
13 (sodium-dependent dicarboxylate transporter), member 3 (SLC13A3) (p=9.8x10-5), 
gliomedin (GLDN) (p=0.0004), claudin 8 (CLDN8) (p=0.0009), urotensin-2 (UTS2) 
(p=0.002) and decreased expression of two pore segment channel 2 (TPCN2) 
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(p=0.007) (Figure 5A-E). SLC8A1 transcript levels in whole blood were not influenced 
by SLC8A1 rs13017968 genotype, although we cannot rule out an effect of the risk 
allele on gene expression in other tissues (Figure 5F). No differential expression of 
SLC8A1 by genotype was noted in the EBV-transformed B cells used for the calcium 
flux experiments and the GTEx database (http://www.gtexportal.org/home/) showed no 
influence of the rs13017968 genotype on SLC8A1 expression in different cell types 
listed in the database (data not shown). Although individuals who were homozygous for 
the SLC8A1 risk allele were more likely to develop aneurysms and the risk allele 
influenced transcript levels of SLC13A3, GLDN, CLDN8, UTS2 and TPCN2, transcript 
levels for these genes were not correlated with aneurysm formation or treatment 
response (data not shown).   
Computational analysis of SNP function  
To search possible cell type-specific functions of the three SNPs of SLC8A1, we 
retrieved annotations from Encode and Roadmap using HaploReg 
(http://www.broadinstitute.org/mammals/haploreg/haploreg_v3.php).The three SNPs 
were predicted to lie in an enhancer region in mesenchymal cells, cardiomyocytes, and 
fibroblasts. However, the specific effect of the different alleles in these SNPs on 
enhancer function has not been determined (Supplemental TableS7).  
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Discussion  
Pathway analysis followed by gene stability selection suggested the importance 
of calcium channel genes in KD susceptibility and identified variants in SLC8A1 that 
were independently replicated in a Japanese cohort and were associate with both 
susceptibility to KD and aneurysm formation. Individuals who were homozygous for the 
risk allele had a higher rate of CAA. The cluster of intronic SNPs were located in an 
enhancer region that is active in mesenchymal cells and cardiomyocytes. B cell lines 
homozygous for the risk allele had higher levels of calcium mobilization. NCX1, the 
gene product of SLC8A1, was expressed in inflammatory and myofibroblast-like cells in 
the arterial wall and in cardiomyocytes from KD autopsy tissues.  
Pathway analysis 
Complex genetic diseases such as KD may be influenced by the cumulative 
effect of many variants in diverse biological pathways. These genetic variants, each with 
small effects, may not be identified by standard single-SNP association analysis of 
GWAS data. In addition, different individuals may be susceptible to a disease due to 
genetic variants in different genes in the same pathway that lead to a similar overall 
biologic effect. To overcome this challenge, we performed a pathway analysis using the 
same methodology as previously described for rheumatoid arthritis4. The KD pathway-
based analysis with gene stability selection identified calcium channel genes in the top 
three pathways responsible for the association with KD susceptibility. This suggested 
that the calcium signaling pathway was a key player in influencing susceptibility to KD. 
Four of the five calcium signaling pathway genes (CACNA1C, CACNB2, CACNA2D3 
and RYR2) were not validated in the Japanese GWAS data. This could be due to the 
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marked differences in LD structure between subjects of European and Asian descent at 
these loci and to differences in allele frequencies between the populations tested 
(Supplemental Figure S3, Supplemental Table S6). Further validation of these genetic 
variants in cohorts of European descent is required. Pathway-based analysis with gene 
stability selection may be a helpful tool to discover genetic variants in uncommon, 
complex genetic diseases such as KD, which is rare enough that it is difficult to recruit 
cohorts of sufficient size for robust meta-analyses to identify risk alleles.  
Calcium signaling pathways in KD 
 Calcium signaling pathways affect diverse cellular processes in different cell 
types including lymphocytes, macrophages, endothelial cells, fibroblasts and vascular 
smooth muscle cells, all of which play important roles in KD pathogenesis14, 15. Each cell 
type uses a unique set of components from the calcium signaling toolbox to generate 
signals with different spatial and temporal properties16. Importantly, polymorphisms in 
three calcium pathway genes, ITPKC, ORAI1, and SLC8A1, have now been validated to 
be associated with KD susceptibility and/or aneurysm formation17, 18. The ITPKC 
rs28493229 was excluded from the pathway analysis to avoid false positive results due 
to the strong association of ITPKC with KD. We were unable to confirm an association 
with the ORAI1 rs3741596 reported in Japanese cohorts because of the very low (<1%) 
risk allele frequency of the ORAI1 SNP in individuals of European and Hispanic 
descent. 
SLC8A1 polymorphisms  
The three validated SNPs in SLC8A1 are located 172Kb 5’ upstream of Exon A, 
one of six exons (A-F) that are differentially spliced to create 15 transcript variants 
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(Supplementary Figure S2)19. Tissue-specific expression of these spliced variants has 
been reported19. Of note, the validated genetic variants of SLC8A1 are predicted to be 
in a regulatory region in smooth muscle cells and cardiomyocytes that use Exon A. The 
risk allele frequency (A  allele) of rs13017968 is 0.66 in Asians and 0.28 in European 
descendants. Although susceptibility to KD is 10 to 50-fold higher in Japanese 
compared to various European descent populations, the incidence of aneurysms is 
similar20. Combinations of different genetic variants in the same pathway may influence 
aneurysm formation in different ethnic and racial groups. 
Gene expression and eQTL 
The SLC8A1 variants reported here did not influence the gene’s transcript levels 
in whole blood. However, SLC8A1 SNP rs13017968 was a quantitative trait locus that 
correlated with transcript levels of five genes, SLC13A3, GLDN, CLDN8, UTS2 and 
TPCN2. Of these genes, only UTS2 has a direct link to cardiovascular pathology. UTS2,  
the most potent vasoconstrictor in humans, influences myofibroblast formation in rat 
ventricular fibroblasts leading to fibrosis21-23. UTS2 also influences inflammation as a 
chemoattractant in CD14+ monocytes24. Therefore, increased UTS2 levels in the 
patients with AA risk allele homozygous of rs13017968 may play a role in KD 
pathogenesis. Studies are in progress to determine if SLC8A1 risk allele carriers may 
have increased vascular inflammation mediated in part through UTS2.  
Potential role of NCX1 in KD pathogenesis 
 NCX1, the gene product of SLC8A1, influences many cellular processes that are 
important in KD pathogenesis. KD subjects who were homozygous for the SLC8A1 risk 
allele were more likely to develop coronary artery aneurysms. NCX1 localizes to the cell 
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membrane where it functions as a bi-directional sodium/calcium exchanger. In primary 
human lung macrophages and circulating monocytes cultured in sodium-free medium, 
NCX1 mediates calcium influx and generation of TNFα, a process that can be blocked 
by NCX1 inhibition25. TNFα is known to be an important pro-inflammatory cytokine in 
acute KD and levels are highest in patients who develop CAA26. NCX1 is expressed on 
cells of mesenchymal origin including fibroblasts, smooth muscle cells, and 
myofibroblasts that all play key roles in aneurysm formation in KD patients10, 13, 27-29. 
TGFβ signaling leads to calcium flux in fibroblasts through NCX1 and results in 
increased expression of EMT-related genes including connective tissue growth factor 
(CTGF) and smooth muscle actin13. We have previously reported myofibroblast-like 
cells expressing CTGF in the wall of CAA and NCX1 may influence this process. NCX1 
also regulates cell motility, which was a key upregulated pathway in a transcriptomic 
analysis of acute and convalescent whole blood samples from KD patients11, 28, 29.   
Therapeutic implications 
Blocking the calcium signaling pathway may reduce acute inflammation in 
patients with KD. Cyclosporine inhibits not only calcineurin, thus blocking the 
phosphorylation of the transcription factor NFAT,  but also directly inhibits NCX1 
expression on the cell membrane by inhibiting protein folding by cyclophilin30. 
Fluvastatin, an HMG-CoA reductase inhibitor (statin), decreased NCX1 mRNA and 
protein by inhibiting a small G protein, RhoB, in the cardiomyoblast cell line, H9c231. 
Conversely, lysophosphatidylcholine (LPC) increased NCX1 mRNA and protein by 
activating RhoB32. L-type calcium channel blockers such as amlodipine and verapamil 
have anti-inflammatory effects possibly mediated through blocking monocyte 
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activation33. Clinical trials of both cyclosporine and atorvastatin (NCT01431105) are in 
progress in KD patients in Japan and the U.S.34-36.  The potential for these agents to 
modulate inflammation in acute KD patients may be mediated, in part, through 
decreased expression of NCX1. 
Strengths and limitations 
Pathway analysis allowed us to find genetic variants that were not discovered by 
GWAS in European descent and Japanese KD cohorts. Because there were no 
available European descent cohorts in which to perform validation, we used a Japanese 
cohort to test for association.  Differences in LD structure between the two populations 
may have prevented us from validating additional variants identified through the 
pathway and gene stability analyses. The limited size of our cohort precluded multi-
gene analyses or testing for SNP interactions within the calcium signaling pathway. In 
addition, it is likely that genetic variants in multiple members of calcium signaling 
pathways, such as ITPKC and ORA1, combine with SLC8A1 to influence KD 
susceptibility3. Creation of genetic risk scores to encompass the contribution of multiple 
genetic variants will likely be a productive research avenue. To achieve these goals, we 
will need expanded cohorts and broad collaboration to permit robust validation of initial 
findings. 
 
Conclusions  
 Pathway analysis with gene stability selection is a powerful tool to identify genes 
that influence susceptibility to complex genetic diseases. Variants in genes in the 
calcium signaling pathway are associated with both KD susceptibility and disease 
outcome. The association of SNPs in SLC8A1 with KD susceptibility was confirmed in a 
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Japanese cohort. The gene product of SLC8A1, NCX1, was expressed in spindle-
shaped cells and smooth muscle cells in the vascular wall and myocardium from KD 
autopsies. This sodium/calcium channel protein is a therapeutic target for which 
candidate drugs are already under study. Translation of these findings into new 
therapies will be an important step toward improving outcomes for KD patients.   
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Table 1. Top three significant pathways and the genes responsible for driving the significance of the pathway.  
 
Pathway -log p 
Total 
number of 
genes in the 
pathway 
Genes responsible for driving the 
pathway association 
Acetylcholine pathway  11.0 218 
CACNA1C, CACNB2, SLC8A1, 
PPP2R2A, PRKG1, KCNMA1 
Endothelial release 
factors 9.8 301 
CACNA1C, CACNB2, SLC8A1, 
RYR2, PPP2R2A, PRKG1, 
KCNMA1 
Nitric Oxide pathway 9.6 78 
CACNA1C, CACNB2, SLC8A1, 
PPP2R2A, PRKG1 
 
 
CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit, CACNB2: calcium channel, voltage-
dependent, beta 2 subunit, SLC8A1: Solute Carrier Family 8, Member 1, PPP2R2A: protein phosphatase 2, regulatory 
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subunit B, alpha, PRKG1: protein kinase, cGMP-dependent, type I, KCNMA1: potassium channel, calcium activated large 
conductance subfamily M alpha, member 1, RYR2: ryanodine receptor 2, Genes belonging to calcium ion transport 
(GO:0006816) in bold.  
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Table 2. Genes and SNPs discovered in the gene stability analysis and validated in a Japanese cohort  
 
 
 
 
 
 
 
 
 
  
Gene Chr. SNP 
European descent   Japanese   
Combined 
p-value 
Risk 
allele OR p   
Risk 
allele OR p   
SLC8A1 2 rs10490051 G 1.25 0.005 
 
G 1.23 0.010 
 
0.00015 
rs13017968 A 1.24 0.008 
 
A 1.24 0.006 
 
0.00014 
rs12989852 A 1.29 0.0006 
 
A 1.18 0.048 
 
0.00013 
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Table 3. Characteristics of subjects (n=161) stratified by genotype of SLC8A1 rs13017968. A is 
the risk allele. 
  SLC8A1 rs13017968   
 
AA AC+CC 
 
  n=25 n=136 P* 
Male, n (%) 14 (56) 82 (60) NS 
Age, years  median (IQR) 2.0 (0.8-4.2) 2.7 (1.5-4.1) NS 
Illness Day,  median (range)† 6 (3-10) 6 (2-10) NS 
    
Ethnicity, n (%)‡ 
   
Asian 11 (44) 17 (13) NA 
African-American 0 (  0)  6  (  4) NA 
Caucasian 3 (12) 39 (29) NA 
Hispanic 6 (24) 36 (26) NA 
More than one race  5 (20) 38 (28) NA 
 
   
Coronary artery status 
   
       Aneurysms, n (%)   5 (20)§ 13 (10) 0.018| | 
       Dilated, n (%)   9 (36) 27 (20) 
 
       Normal, n (%) 11 (44) 96 (70) 
 
Z-worst, median (IQR) 2.8 (1.3-3.5) 1.7 (1.1-2.6) 0.0497 
 
   
IVIG resistance, n (%) 3 (15) 32 (24) NS 
 
   
Pre-treatment laboratory data, median (IQR) 
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WBC, ×103/mm3 14 (12.3-18.7) 13.6 (10.7-18.6) NS 
Absolute Lymph, ×103/mm3 3.2 (1.8-4.2) 2.8 (1.6-4.5) NS 
Absolute Mono, ×103/mm3 0.8 (0.5-1.1) 0.6 (04-1.1) NS 
Platelet count, ×103/mm3 448 (284-578) 396 (313-467) NS 
ESR, mm/h 61 (48-90) 60 (44-79) NS 
CRP, mg/dl 12.5 (6.4-17.5) 8.0 (4.9-15.4) NS 
  
  
*: p-values were calculated by Mann–Whitney U test for continuous variables and chi 
test for categorical variables except ethnicity comparison. †: Illness day 1: first 
calendar day of fever. ‡: The frequencies of individuals homozygous for the risk allele 
in the 1000 genome database, were follows: East Asians: 40.3%, European descent: 
6.6%, and Hispanic: 10.4%.  §: Ethnicities of five patients were two Asians, two 
Hispanics and one mixture of Asian and Caucasian.  | |: Fisher's exact T-test. 
aneurysm+Dilated comparing to Normal. Relative risk:1.9, 95% CI: 1.2-2.9. IVIG: Intra 
venous immunoglobulin G therapy CRP: C-reactive protein, ESR: Erythrocyte 
sedimentation rate, WBC: White blood cell count, NS: not significant, NA: not 
applicable. 
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Figure legends 
 
Figure 1. Workflow of study 
A. Pathway analysis and gene stability selection 
B. Influence of SLC8A1 on KD pathogenesis   
CAA: coronary arterial aneurysms, SMC: smooth muscle cells, ECG: electrocardiogram, 
GO: Gene Ontology, CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C 
subunit, CACNA2D3: calcium channel, voltage-dependent, alpha 2/delta subunit 3, 
CACNB2: calcium channel, voltage-dependent, beta 2 subunit, SLC8A1: solute Carrier 
Family 8, Member 1, KCNMA1: potassium channel, calcium activated large 
conductance subfamily M alpha, member 1, RYR2: ryanodine receptor 2, PPP2R2A: 
protein phosphatase 2 regulatory subunit B, alpha, PRKG1: protein kinase, cGMP-
dependent, type I. Font in red: calcium signaling pathway genes     
 
Figure 2. Association with KD susceptibility was validated for three SNPs in 
SLC8A1 in the same LD block  
A. Association results using imputed GWAS data were plotted against chromosome 
location. Red dots showed the validated SNPs (rs10490051, rs13017968 and 
rs12989852). SLC8A1 is encoded on the negative strand so the gene structure is 
shown 3’ to 5’. B. Location of the three validated SNPs and their LD block in European 
decent (EUR) and Japanese (JPT).  
 
Figure 3. Immunohistochemical staining of aneurysmal wall from KD autopsy 
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Aneurysmal wall of coronary arteries (A-D) and myocardium (G-J) from KD autopsies of 
a 3y7m-old child who died on illness day 7 (A, B, G and H) and a 3 month-old infant 
who died on illness day 12 (C, D, I and J) and a control coronary artery (E and F) and 
myocardium (K and L) from a 9 month-old infant who died from pneumonia were stained 
with NCX1 antibody (A, C, E, G, I, and K) and rabbit IgG for control (B, D, F, H, J, and 
L). Squares 1-4 in A, C and E are magnified (x400)  in A1-A4, C1-C4 and E1-E3. NCX1 
was expressed in  spindle-shaped cells in the intima (A1 and C1), smooth muscle cells 
(A2 and C2), fibroblasts (A3 and C3) and small round inflammatory cells (A4 and C4). 
Coronary artery from control patient showed no staining for NCX1 (E1-3). 
Cardiomyocytes from KD autopsies showed positive staining of NCX1 but not from 
infant who died from pneumonia (G, I and K). lu: lumen, IEL: internal elastic lamina, m: 
media, a: adventitia, i: intima, Black bars: 100µm for A-F, 10µm for magnified photos 
and 50µm for G-L. 
 
Figure 4. SCL8A1 genotype is associated with differences in intracellular Ca2+ 
levels at rest and with stimulation. 
Mean fluorescence Intensity (MFI) of Fluo-4AM (Y-axis) acquired by Fluorescence-
activated cell sorting (FACS) of EBV transfected B-cells from various SLC8A1 
genotypes [AA (n=3), CA (n=2) and CC (n=3)] plotted against time (X-axis). Graph 
represents average MFI of 3 repeats from each SLC8A1 genotypes. 
 
Figure 5. Transcript levels in whole blood 
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Transcript levels in whole blood during acute phase stratified by SLC8A1 rs13017968 
genotype (AA n=24, AC n=68, CC n=54) for SLC13A3 (A), GLDN (B), CLDN8 (C), UTS2 
(D), TPCN2 (E), and SLC8A1 (F). p-values were calculated using Kruskal-Wallis test for 
A-F. The boxies go from the first quartiles to the third quartiles, the horizontal lines in the boxies 
are drawn at the median and the whiskers go from the minimum to the maximum. SLC13A3: 
located on the basolateral membrane of epithelial cells and transports dicarboxylates in 
a sodium-dependent manner. GLDN: an adhesion molecule that plays a central role in 
the formation of nodes of Ranvier and myelin sheath gaps. CLDN8: a component of 
tight junction strands. TPCN2: localizes to lysosomal membranes and enables nicotinic 
acid adenine dinucleotide phosphate (NAADP)-induced calcium ion release from 
lysosomal stores. UST2, SLC8A1: see text.  
 
